Program
Aurora B/VEGFR/FGFR Inhibitor AL8326
Also written as “AL8326 tablets”, “AL8326 40 mg” and “AL8326 60 mg”.
Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung, led by 3 companies.
Drug pageAurora B/VEGFR/FGFR Inhibitor AL8326: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Advenchen Laboratories Nanjingits history only | 51 open or running | phase 3since Oct 9, 2023 | Apr 26, 2021 | Jul 2028phase 3 · NCT06247605 |
| Advenchen Laboratoriesits history only | 22 open or running | phase 2since Sep 28, 2025 | Jan 30, 2024 | Dec 2027phase 1 · NCT06794957 |
| Advenchen Pharmaceuticals, LLC.its history only | 11 open or running | phase 2since Apr 22, 2022 | Apr 22, 2022 | Dec 2027phase 2 · NCT05363280 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 26, 2021First study: phase 2 study in Small Cell Lung CarcinomaNew to Advenchen Laboratories NanjingAdvenchen Laboratories Nanjing · NCT04890795 · 237 enrolled · China
- Apr 26, 2021Phase 1 study in Advanced Solid TumorsAdvenchen Laboratories Nanjing · NCT04890587 · 40 enrolled · China
- Apr 22, 2022Advenchen Pharmaceuticals, LLC.’s first study: phase 2 study in Small Cell Lung CarcinomaNew to Advenchen Pharmaceuticals, LLC.Advenchen Pharmaceuticals, LLC. · NCT05363280 · 80 planned · United States, Spain
- Jun 2, 2022Phase 1 study in Diet, High-FatAdvenchen Laboratories Nanjing · NCT05486598 · 16 enrolled · China
- Oct 9, 2023Phase 3 study in Small Cell Lung CarcinomaAdvenchen Laboratories Nanjing · NCT06247605 · 243 planned · China
- Jan 30, 2024Advenchen Laboratories’ first study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to Advenchen LaboratoriesAdvenchen Laboratories · NCT06794957 · 158 enrolled · China
- Feb 19, 2025Phase 1 study in Small Cell Lung CarcinomaAdvenchen Laboratories Nanjing · NCT07132957 · 6 enrolled · China
- Sep 28, 2025Phase 2 study in Solid TumorAdvenchen Laboratories · NCT07392736 · 228 planned · China
Ahead
- Dec 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungAdvenchen Laboratories · NCT06794957
- Dec 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaAdvenchen Pharmaceuticals, LLC. · NCT05363280
- Jul 2028Primary completion: phase 3 study in Small Cell Lung CarcinomaAdvenchen Laboratories Nanjing · NCT06247605
- Nov 7, 2029Primary completion: phase 2 study in Solid TumorAdvenchen Laboratories · NCT07392736
TargetBeta
“An orally bioavailable inhibitor of the receptor kinases Aurora B, fibroblast growth factor receptor (FGFR), and vascular endothelial growth factor receptor (VEGFR), ”NCIt, by rule
Other programs on KDR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lenvatinibrule | Eisai | phase 4 | 81 |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| cabozantinibrule | Exelixis | phase 4 | 36 |
| Ramucirumabrule | Eli Lilly | phase 3 | 58 |
| apatinibrule | Jiangsu HengRui Medicine | phase 3 | 47 |
| Axitinibrule | Pfizer | phase 3 | 45 |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 40 |
| vorolanibrule | Betta Pharmaceuticals | phase 3 | 24 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
| AXL/FLT3/VEGFR2 Inhibitor KC1036rule | beijing-konruns-pharmaceutical-co-ltd | phase 3 | 7 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07392736Solid Tumor · China | 2 | Recruiting | Advenchen Laboratories | Nov 7, 2029 | 228 |
| NCT07132957Small Cell Lung Carcinoma · China | 1 | Completed | Advenchen Laboratories Nanjing | May 17, 2025 | 6 |
| NCT06794957Carcinoma, Non-Small-Cell Lung · China | 1 | Active, not recruiting | Advenchen Laboratories | Dec 2027 | 158 |
| NCT06247605Small Cell Lung Carcinoma · China | 3 | Recruiting | Advenchen Laboratories Nanjing | Jul 2028 | 243 |
| NCT05486598Diet, High-Fat · China | 1 | UNKNOWN | Advenchen Laboratories Nanjing | Dec 2022 | 16 |
| NCT05363280Small Cell Lung Carcinoma · United States, Spain | 2 | Recruiting | Advenchen Pharmaceuticals, LLC. | Dec 2027 | 80 |
| NCT04890795Small Cell Lung Carcinoma · China | 2 | UNKNOWN | Advenchen Laboratories Nanjing | Sep 2021 | 237 |
| NCT04890587Advanced Solid Tumors · China | 1 | UNKNOWN | Advenchen Laboratories Nanjing | Dec 2023 | 40 |
How it is read
Names in the registry
- “AL8326 tablets”, 6 entries
- “AL8326 40 mg”, 1 entry
- “AL8326 60 mg”, 1 entry
- “AL8326 80 mg--stopped”, 1 entry
- “14C-labeled AL8326”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 4 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.